A first-in-human Phase 1/2 clinical trial of TLC-590 in subjects undergoing hernia repair surgery in escalating dose cohorts compared to free non-liposomal ropivacaine

Trial Profile

A first-in-human Phase 1/2 clinical trial of TLC-590 in subjects undergoing hernia repair surgery in escalating dose cohorts compared to free non-liposomal ropivacaine

Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Ropivacaine (Primary) ; Ropivacaine
  • Indications Postoperative pain
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 09 Apr 2018 New trial record
    • 03 Apr 2018 According to a Taiwan Liposome Company media release, the company has applied with the U.S. Food and Drug Administration (FDA) for the proceeding of TLC590 as an Investigational New Drug (IND).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top